Fanizzi Fabrizio, Allocca Mariangela, Fiorino Gionata, Zilli Alessandra, Furfaro Federica, Parigi Tommaso Lorenzo, Peyrin-Biroulet Laurent, Danese Silvio, D'Amico Ferdinando
Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Milan, Italy.
Gastroenterology and Digestive Endoscopy, San Camillo-Forlanini Hospital, Rome, Italy.
Therap Adv Gastroenterol. 2024 Nov 24;17:17562848241273066. doi: 10.1177/17562848241273066. eCollection 2024.
Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by growing incidence and prevalence around the world in the last few decades. The range of available existing treatment and strategies for its management is being implemented. Given the introduction of newly developed molecules and the lack of specific guidelines, drug positioning may represent a tough clinical challenge. UC management is mostly medical, and it has been shifting toward a more personalized approach with the aim to create a tailored strategy depending on the patient's profile. A treat-to target strategy seems to be the best approach to reach disease control as it allows to carry out therapeutic choices based on objective and specific parameters: histological, ultrasonographic, and molecular targets may add to the already used clinical, endoscopic, and biochemical targets. In addition, dual-targeted therapy has emerged as an attractive therapeutic strategy for patients not achieving remission. This review aims to provide an overview of the available strategies to raise the bar in UC.
溃疡性结肠炎（UC）是一种慢性炎症性肠病，在过去几十年中，其发病率和患病率在全球范围内呈上升趋势。现有的治疗方法和管理策略正在不断实施。鉴于新开发分子的引入以及缺乏具体指南，药物定位可能是一项严峻的临床挑战。UC的管理主要是医学方面的，并且一直在朝着更加个性化的方法转变，旨在根据患者的情况制定量身定制的策略。治疗达标策略似乎是实现疾病控制的最佳方法，因为它允许根据客观和具体参数进行治疗选择：组织学、超声和分子靶点可能会补充已使用的临床、内镜和生化靶点。此外，双靶点治疗已成为未实现缓解的患者的一种有吸引力的治疗策略。本综述旨在概述提高UC治疗标准的可用策略。
